Both the American Diabetes Association guidelines and the recommendations published in The New England Journal of Medicine indicate that in men with erectile dysfunction coexisting with metabolic or cardiovascular diseases, family physicians should consider PDE-5 inhibitors as first-line therapy, after excluding contraindications, especially the concomitant use of nitrates [27,28]. The gene discussed is PDE5A; the disease is cardiovascular disorder.